[Utilization of antineoplastic agents in Sweden and Europe].
Wilking
Nils
N
Karolinska institutet, Stockholm. nils.wilking@ki.se
Jönsson
Bengt
B
Björn
Wettermark
W
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D013548:Sweden / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents